EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab

Lewis E Tomalin, Frank Kolbinger, Maria Suprun, Keith A Wharton, Nicole Hartmann, Thomas Peters, Anton Glueck, Marina Milutinovic, James G Krueger, Mayte Suárez-Fariñas

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llae006 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Lewis E Tomalin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Science and Policy, Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Interleukin-17, Transcriptome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Novartis Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Secukinumab, an anti-interleukin (IL)-17A monoclonal antibody, induces histological and molecular resolution of psoriatic plaques by 12 weeks. However, the long-term effects of secukinumab on the molecular resolution of psoriatic inflammation remain unknown.

Objectives

To investigate the molecular resolution of psoriasis following 52 weeks of secukinumab treatment.

Methods

This was a two-part phase II randomized double-blinded placebo-controlled 52-week study of patients with moderate-to-severe psoriasis receiving secukinumab 300 mg (NCT01537432). Psoriatic lesional and nonlesional skin biopsies were obtained at baseline and at weeks 12 and 52, and the composition of the residual disease genomic profile (RDGP; i.e. ‘molecular scar’) of biopsies from secukinumab responders analysed.

Results

After 52 weeks of treatment, 14 of 24 enrolled patients were considered to be clinical responders [≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75)], 4 of 24 were considered to be nonresponders (< PASI 75) and 6 of 24 patients were lost to follow-up; both the histological and transcriptomic profiles of PASI 75 responders improved from week 12 to week 52. RDGP transcripts of histological responders only partially overlapped between weeks 12 and 52, despite a similar number of transcripts in each RDGP; specifically, four novel transcript subsets showed distinct expression dynamics between weeks 12 and 52 (‘slow-resolving’, ‘recurring’, ‘persistent’ and ‘resolved’), with anti-inflammatory and immunomodulatory genes (e.g. SOCS1, CD207 and IL37) notably restored at week 52. Shorter disease duration prior to secukinumab treatment coincided with greater transcript improvements at weeks 12 and 52.

Conclusions

Secukinumab improves the histological and molecular phenotype of psoriatic lesional skin up to 52 weeks of treatment; these results suggest possible mechanisms that drive long-term control of psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedInterleukin-17TranscriptomeHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedAntibodies, MonoclonalSeverity of Illness IndexBiomarkersSkinTreatment Outcome

Substanzen

secukinumabAntibodies, Monoclonal, HumanizedInterleukin-17Antibodies, MonoclonalIL17A protein, humanBiomarkers

Autor:innen und Institutionen

  • Department of Population Health Science and Policy, Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Novartis Biomedical Research, Basel, Switzerland.
  • Novartis Biomedical Research, Cambridge, MA, USA.
  • Ultivue, Inc., Cambridge, MA, USA.
  • Novartis Pharma AG, Basel, Switzerland.
  • Laboratory of Investigative Dermatology, Rockefeller University, New York, NY, USA.

Förderung

  • Novartis Pharma

Zitieren

APA

Tomalin, L. E., Kolbinger, F., Suprun, M., Wharton, K. A., Hartmann, N., Peters, T., Glueck, A., Milutinovic, M., Krueger, J. G., & Suárez-Fariñas, M. (2024). Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae006

Vancouver

Tomalin LE, Kolbinger F, Suprun M, Wharton KA, Hartmann N, Peters T, et al. Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae006

BibTeX
@article{Tomalin2024,
  author = {Tomalin, Lewis E and Kolbinger, Frank and Suprun, Maria and Wharton, Keith A and Hartmann, Nicole and Peters, Thomas and Glueck, Anton and Milutinovic, Marina and Krueger, James G and Suárez-Fariñas, Mayte},
  title = {Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llae006}
}
Kostenlos starten →